Creating a New Kind of Doctor
We recruit and train physician leaders as comfortable taking on systemic challenges in health as caring for individual patients.
Discovery to Impact — Faster
We reward creative thinking and encourage rapid experimentation, using collaborative programs to speed promising research to market.
Improving Care. Improving Health.
We’re here to make health — including health care — better. The end goal is a complete revolution in how people get and stay healthy.
In This Section
More Information
Health in the Landscape of Life
Enabling the healthscape, the ecosystem outside the clinic, requires improving the system to pay for health drivers.
More Information
Meet Dell Med
We’re rethinking the role of academic medicine in improving health — and doing so with a unique focus on our community.
More Information
Make an Appointment Give Faculty Students Alumni Directory

Linda Feagins, M.D.


Baylor College of Medicine


Residency, Internal Medicine
University of Texas Southwestern Medical Center

Fellowship, Gastroenterology
University of Texas Southwestern Medical Center


Linda Feagins, M.D., is a board-certified gastroenterologist and director of the Center of Inflammatory Bowel Disease at Digestive Health, a clinical partnership between Dell Med and Ascension Seton. Before joining Dell Med, Feagins was an associate professor at The University of Texas Southwestern Medical Center and VA Hospital in Dallas. She was also the director of the inflammatory bowel disease program at the VA North Texas from 2008 until 2019.

Feagins has done research on preventing post-polypectomy bleeding during colonoscopy. With competitive grant funding from VA Hospital, she published the first prospective estimates of the rates of post-polypectomy bleeding with uninterrupted use of antiplatelets. She also led a large multi-center trial investigating the role of prophylactic hemoclips to prevent delayed bleeding. The study found that hemoclips did not reduce the risk of bleeding when placed after removal of polyps 1cm in size or larger. The study was published in Gastroenterology.

Feagins’ other area of research interest is in improving care for patients with IBD. Her projects include predicting the risk of flare up for patients with IBD using histology and biomarkers (such as epithelial tight junction proteins), better understanding the onset and course of IBD in older patients, sexual health in men with IBD, role of diet in IBD and the effects of radiation for prostate cancer in men with IBD. In addition to ongoing investigator-initiated studies, she is building a sponsored clinical trials program for IBD at Dell Med to bring new therapy options for patients in Austin.

Feagins has served on several National Scientific Advisory Committees for the Crohn’s and Colitis Foundation, FDA Related Matters Committee for the American College of Gastroenterology and abstract review committee for the American Gastroenterological Association. She also served five years on the Gastrointestinal Drug Advisory Board for the FDA.

Professional Affiliations
  • American College of Gastroenterology
    FDA Related Matters Committee, 2018–2021
  • American Gastroenterology Association
    DDW Abstract Selection Committee, 2016–present
  • American College of Physicians
  • Crohn’s & Colitis Foundation
    National Scientific Advisory Committees, 2008–present
  • American Society for Gastrointestinal Endoscopy
Awards & Honors
  • Fellow
    American College of Gastroenterology, 2019
  • Fellow
    American Gastroenterology Association, 2016
  • Awardee
    AGA Women’s Leadership Conference, 2015
  • Graduate
    UT Southwestern LEAD Program, 2012
  • CCFA National Visiting Fellow IBD Program
    University of California, San Francisco, 2008